Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chester V Oddis

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Frontiers in Immunology|June 19, 2024
Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndromeKoichi Yamaguchi, Qi Tang, Paul Poland, et al.
Arthritis and Rheumatism|May 10, 2005
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositisShinji Sato, Michito Hirakata, Masataka Kuwana, et al.
Rheumatology (Oxford, England)|March 9, 2024
A patient-centred assessment of the 2016 ACR-EULAR Myositis Response Criteria: evaluating the meaningfulness of responsesDidem Saygin, Anjana Chandrasekhara Pillai, Siamak Moghadam-Kia, et al.
Clinical Rheumatology|August 26, 2024
Internet-based enrollment of a myositis patient cohort-a national experienceRaisa Lomanto Silva, Shiri Keret, Tanya Chandra, et al.
Rheumatology (Oxford, England)|December 20, 2014
Anti-signal recognition particle autoantibody ELISA validation and clinical associationsRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|February 19, 2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|July 8, 2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|November 21, 2013
Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validationRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Respiratory Medicine|December 6, 2017
Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositisCheilonda Johnson, Paul Rosen, Thomas Lloyd, et al.
Rheumatology (Oxford, England)|January 14, 2017
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosisRohit Aggarwal, Christine McBurney, Frank Schneider, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Frontiers in Immunology|June 19, 2024
Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndromeKoichi Yamaguchi, Qi Tang, Paul Poland, et al.
Arthritis and Rheumatism|May 10, 2005
Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositisShinji Sato, Michito Hirakata, Masataka Kuwana, et al.
Rheumatology (Oxford, England)|March 9, 2024
A patient-centred assessment of the 2016 ACR-EULAR Myositis Response Criteria: evaluating the meaningfulness of responsesDidem Saygin, Anjana Chandrasekhara Pillai, Siamak Moghadam-Kia, et al.
Clinical Rheumatology|August 26, 2024
Internet-based enrollment of a myositis patient cohort-a national experienceRaisa Lomanto Silva, Shiri Keret, Tanya Chandra, et al.
Rheumatology (Oxford, England)|December 20, 2014
Anti-signal recognition particle autoantibody ELISA validation and clinical associationsRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|February 19, 2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|July 8, 2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Rheumatology (Oxford, England)|November 21, 2013
Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validationRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.
Respiratory Medicine|December 6, 2017
Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositisCheilonda Johnson, Paul Rosen, Thomas Lloyd, et al.
Rheumatology (Oxford, England)|January 14, 2017
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosisRohit Aggarwal, Christine McBurney, Frank Schneider, et al.
Pageof 17